Medicinova Inc

This management proposal requests stockholder approval to amend the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 247,000,000. Management and the Board present this amendment to provide the company with greater flexibility to issue equity for corporate purposes without the delay and cost of special stockholder approval, citing potential future uses including equity incentive plan awards, public or private financings, licenses, partnerships, collaborations, strategic investments and other corporate transactions. The proposal includes specific amendment language (also shown in Appendix A) replacing the current Section A to set total authorized capital at 250,000,000 shares, with 247,000,000 common and 3,000,000 preferred shares, and specifying par values. The Board emphasizes that the additional shares would be identical in rights to existing common stock, and cautions that issuance could dilute earnings per share, shareholders’ equity and voting power. The filing states the Board has not adopted this increase with the intent to discourage takeover attempts, but acknowledges that the availability of additional shares could have the effect of discouraging unsolicited transactions. Stockholder approval requires a majority of outstanding common shares, and abstentions or broker non-votes have the same effect as “Against.” The Board recommends a vote FOR, framing the change as prudent planning to maintain financial and strategic flexibility to strengthen the company’s position and pursue collaborations and financings expeditiously. From a governance perspective, the proposal raises standard dilution risk and timing considerations: while it enables rapid capital raising and incentive issuance, it removes an additional layer of mandatory shareholder approval for future issuances of the newly authorized shares, increasing the importance of Board stewardship and disclosure around any material issuances. Analysts evaluating this proposal should weigh the operational benefits of transaction agility and equity compensation capacity against dilutionary impacts and potential governance concerns over open-ended share authorization.

This management proposal seeks authorization for the proxies solicited by the Board to adjourn the Annual Meeting to a later date or dates if necessary to permit additional solicitation of proxies and votes in the event insufficient votes exist to approve one or more proposals. Management frames the adjournment authority as a procedural mechanism to allow the Board to continue to solicit support and to avoid immediate defeat of proposals due solely to temporary lack of votes; the Company notes that any proxies in which no voting instructions are provided will be voted in favor of adjournment under these circumstances. The adjournment vote requires a majority of shares present or represented and entitled to vote; abstentions count as against. The Board recommends a vote FOR to preserve flexibility to continue outreach to stockholders and permit revocation and re‑voting by shareholders who have already submitted proxies. From a shareholder-rights perspective, while adjournment can be a reasonable and limited tool for securing a quorum of affirmative votes, it can also delay finality and extend the period during which company actions remain unresolved. Analysts should consider the frequency and likely duration of any adjournments, whether the Board has a credible plan to secure additional votes (e.g., targeted outreach to large holders or brokers), and the potential for repeated adjournments which could be perceived negatively by markets or activist investors. Overall, the proposal is a standard meeting-management measure that preserves Board discretion to seek broader shareholder support before implementing substantive changes.

This item reserves the meeting agenda slot to transact any other business that may be properly presented at the Annual Meeting or any adjournment, as permitted under Delaware law and the Company's governing documents. The proxy materials state that the Board is not aware of any other business to be acted upon, and that proxies have discretionary authority to vote on any other properly presented matters. For stockholders, the practical effect is that unexpected or late-submitted proposals that meet notice and procedural requirements could be voted on, with management proxies exercising their discretion if no specific direction is provided. Analysts should note that under the Company’s bylaws, stockholder proposals typically must be timely and meet documentary requirements to be properly brought; consequently, this item rarely results in substantive new actions unless pre-noticed. Because no specific recommendation is given, and because the Board indicates it currently expects no additional business, the item functions as a procedural placeholder; its presence does not imply anticipated material corporate actions beyond those expressly described in the proxy statement.